Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL

NCT06930105 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoid Leukemia (ALL)

Interventions

DRUG: Blinatumomab plus Reduced-dose Chemotherapy

Sponsor

Xianmin Song, MD